FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016716920> ?p ?o ?g. }

• W2016716920 endingPage "R103" @default.
• W2016716920 startingPage "R103" @default.
• W2016716920 abstract "In this study, we compare the health-related quality of life (HRQoL) of patients with moderate-to-severe rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS), and study the effect of treatment with infliximab on the HRQoL of patients with these diseases. Short Form Health Survey-36 (SF-36) data from the placebo-controlled phases of 4 studies of infliximab in patients with inflammatory rheumatic diseases (n = 1990) were evaluated. Data came from the Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) (n = 428), the Safety Trial for Rheumatoid Arthritis with REMICADE Therapy (START) (n = 1083), the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) (n = 279), and the Infliximab Multinational Psoriatic Arthritis Clinical Trial II (IMPACT II) (n = 200). SF-36 assessments were made at weeks 0, 10, 30, and 54 in ATTRACT, weeks 0, 6, and 22 in START, weeks 0, 12, and 24 in ASSERT, and weeks 0 and 14 in IMPACT II. All patient populations had significantly impaired physical aspects of HRQoL at baseline relative to the general population of the United States, and the magnitude of impairment was similar across the diseases. Mean baseline physical component summary scores were 29 in the RA cohort, 32 in the PsA cohort, and 29 in the AS cohort. In all 3 diseases, patients who received infliximab showed significant improvement in physical component summary scores compared with those who received placebo. The magnitude of the difference of improvement (effect size, 95%CI) between infliximab and placebo groups was similar in the AS (10.1, 9.2-11.0), PsA (8.6, 7.8-9.4), and RA (10.1, 9.2-11.0) cohorts. Patients with RA and those with PsA treated with infliximab also showed greater improvement in the mental component summary score than those in the placebo group with an effect size of 4.6 (4.2-5.1) in RA and 2.7 (2.4-3.1) in PsA. Patients in large randomized controlled studies of infliximab in RA, PsA, and AS had similar impairment in physical aspects of HRQoL at baseline and showed significantly greater improvement in HRQoL after treatment with infliximab." @default.
• W2016716920 created "2016-06-24" @default.
• W2016716920 creator A5001440423 @default.
• W2016716920 creator A5006123817 @default.
• W2016716920 creator A5032879772 @default.
• W2016716920 creator A5034158558 @default.
• W2016716920 creator A5050721137 @default.
• W2016716920 creator A5058110978 @default.
• W2016716920 creator A5069831361 @default.
• W2016716920 creator A5087991365 @default.
• W2016716920 creator A5089158758 @default.
• W2016716920 creator A5090753435 @default.
• W2016716920 date "2007-01-01" @default.
• W2016716920 modified "2023-10-18" @default.
• W2016716920 title "The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases" @default.
• W2016716920 cites W1985763670 @default.
• W2016716920 cites W1994065448 @default.
• W2016716920 cites W1999649023 @default.
• W2016716920 cites W2007517418 @default.
• W2016716920 cites W2037377025 @default.
• W2016716920 cites W2051986755 @default.
• W2016716920 cites W2060886633 @default.
• W2016716920 cites W2081388746 @default.
• W2016716920 cites W2113411136 @default.
• W2016716920 cites W2135530788 @default.
• W2016716920 cites W2139788459 @default.
• W2016716920 cites W2145778588 @default.
• W2016716920 cites W2146002757 @default.
• W2016716920 cites W2319957449 @default.
• W2016716920 doi "https://doi.org/10.1186/ar2306" @default.
• W2016716920 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2212571" @default.
• W2016716920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17922913" @default.
• W2016716920 hasPublicationYear "2007" @default.
• W2016716920 type Work @default.
• W2016716920 sameAs 2016716920 @default.
• W2016716920 citedByCount "42" @default.
• W2016716920 countsByYear W20167169202012 @default.
• W2016716920 countsByYear W20167169202013 @default.
• W2016716920 countsByYear W20167169202014 @default.
• W2016716920 countsByYear W20167169202015 @default.
• W2016716920 countsByYear W20167169202018 @default.
• W2016716920 countsByYear W20167169202019 @default.
• W2016716920 countsByYear W20167169202020 @default.
• W2016716920 countsByYear W20167169202022 @default.
• W2016716920 crossrefType "journal-article" @default.
• W2016716920 hasAuthorship W2016716920A5001440423 @default.
• W2016716920 hasAuthorship W2016716920A5006123817 @default.
• W2016716920 hasAuthorship W2016716920A5032879772 @default.
• W2016716920 hasAuthorship W2016716920A5034158558 @default.
• W2016716920 hasAuthorship W2016716920A5050721137 @default.
• W2016716920 hasAuthorship W2016716920A5058110978 @default.
• W2016716920 hasAuthorship W2016716920A5069831361 @default.
• W2016716920 hasAuthorship W2016716920A5087991365 @default.
• W2016716920 hasAuthorship W2016716920A5089158758 @default.
• W2016716920 hasAuthorship W2016716920A5090753435 @default.
• W2016716920 hasBestOaLocation W20167169201 @default.
• W2016716920 hasConcept C126322002 @default.
• W2016716920 hasConcept C142724271 @default.
• W2016716920 hasConcept C159110408 @default.
• W2016716920 hasConcept C17991360 @default.
• W2016716920 hasConcept C1862650 @default.
• W2016716920 hasConcept C197934379 @default.
• W2016716920 hasConcept C198451711 @default.
• W2016716920 hasConcept C203014093 @default.
• W2016716920 hasConcept C204787440 @default.
• W2016716920 hasConcept C27081682 @default.
• W2016716920 hasConcept C2776260265 @default.
• W2016716920 hasConcept C2777077863 @default.
• W2016716920 hasConcept C2777138892 @default.
• W2016716920 hasConcept C2777402515 @default.
• W2016716920 hasConcept C2777575956 @default.
• W2016716920 hasConcept C2779384505 @default.
• W2016716920 hasConcept C2779951463 @default.
• W2016716920 hasConcept C2780564577 @default.
• W2016716920 hasConcept C2908647359 @default.
• W2016716920 hasConcept C71924100 @default.
• W2016716920 hasConcept C72563966 @default.
• W2016716920 hasConcept C99454951 @default.
• W2016716920 hasConceptScore W2016716920C126322002 @default.
• W2016716920 hasConceptScore W2016716920C142724271 @default.
• W2016716920 hasConceptScore W2016716920C159110408 @default.
• W2016716920 hasConceptScore W2016716920C17991360 @default.
• W2016716920 hasConceptScore W2016716920C1862650 @default.
• W2016716920 hasConceptScore W2016716920C197934379 @default.
• W2016716920 hasConceptScore W2016716920C198451711 @default.
• W2016716920 hasConceptScore W2016716920C203014093 @default.
• W2016716920 hasConceptScore W2016716920C204787440 @default.
• W2016716920 hasConceptScore W2016716920C27081682 @default.
• W2016716920 hasConceptScore W2016716920C2776260265 @default.
• W2016716920 hasConceptScore W2016716920C2777077863 @default.
• W2016716920 hasConceptScore W2016716920C2777138892 @default.
• W2016716920 hasConceptScore W2016716920C2777402515 @default.
• W2016716920 hasConceptScore W2016716920C2777575956 @default.
• W2016716920 hasConceptScore W2016716920C2779384505 @default.
• W2016716920 hasConceptScore W2016716920C2779951463 @default.
• W2016716920 hasConceptScore W2016716920C2780564577 @default.
• W2016716920 hasConceptScore W2016716920C2908647359 @default.
• W2016716920 hasConceptScore W2016716920C71924100 @default.

• next